Padagis
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Padagis sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Padagis: 17 sponsored US clinical trials, none currently recruiting.
Padagis sponsors 17 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 17 completed. 14 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Secondarily Infected Traumatic Skin Lesions, with 1 trials.
Top-decile sponsor footprint
Padagis ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
17 total, page 1 of 1
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
NCT05763082
To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
NCT04944290
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions
NCT04155203
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
NCT04024072
Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face
NCT03393494
An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
NCT03352323
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
NCT02800148
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy
NCT02770365
Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris
NCT02515305
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
NCT02265913
Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis
NCT02230696
A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)
NCT01673659
Safety and Maintenance Study of Entocort for Children With Crohn's Disease
NCT01453946
Safety Study of Entocort for Children With Crohn's Disease
NCT01444092
A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
NCT01039584
Bioavailability of Prochlorperazine Suppositories, 25 mg
NCT00992472
A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions
NCT00992238
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 14 |
Therapeutic Areas
How the Padagis archive is shaped
17 indexed studies, none listed as recruiting (0% open); 17 completed (100%).
Phase mix: 14 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Secondarily Infected Traumatic Skin Lesions (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Padagis: archived-pipeline peers nationwide
Peers matched on 17 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Padagis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 archived trials
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Padagis page
17 registered trials is a research-attention snapshot, not an endorsement of Padagis or any single study.
- None of Padagis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Secondarily Infected Traumatic Skin Lesions is the condition Padagis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Secondarily Infected Traumatic Skin Lesions trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Padagis pipeline card: 17 registered trials from official public datasets.Report a data error.